U.S. Markets open in 5 hrs 48 mins

CytRx Corporation (CYTR)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.61+0.01 (+1.37%)
At close: 4:00PM EDT
People also watch
GALECYCCCRISCVMDCTH

CytRx Corporation

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
310-826-5648
http://www.cytrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees27

Key Executives

NameTitlePayExercisedAge
Mr. Steven A. KriegsmanChairman, CEO & Pres1.01MN/A75
Mr. John Y. CalozCFO, Chief Accounting Officer & Treasurer535kN/A65
Mr. David J. HaenVP of Bus. Devel. & Investor RelationsN/AN/A39
Dr. Shanta Chawla M.D.Sr. VP of Drug Devel.N/AN/AN/A
Dr. Bruce Spiegelman Ph.D.Member of Scientific Advisory Board of CytRx Laboratories IncN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Corporate Governance

CytRx Corporation’s ISS Governance QualityScore as of July 1, 2017 is 10. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.